AlenCiken

IMV Updates Rapid Progress on COVID-19 Vaccine Program

NASDAQ:IMV   None
IMV Updates Rapid Progress on COVID-19 Vaccine Program

-Received agreement with Health Canada on Phase 1 clinical study design protocol which also includes older patients of 56 years and above

-Completed cGMP formulation and manufacturing process development for clinical trials

-Ready and prepared for Clinical Trial Application submission for regulatory approval

"Next milestones are anticipated as we commence phase 1 clinical trials this summer with results in the Fall of 2020. Once results are published, we plan to initiate phase 2 clinical trials in the second half of the year."

www.imv-inc.com/inve...d-19-vaccine-program

finance.yahoo.com/ne...arket-130158025.html


免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。